• Profile
Close

A trial of a shorter regimen for rifampin-resistant tuberculosis

New England Journal of Medicine Mar 18, 2019

Nunn AJ, et al. – In this trial, researchers validated findings from cohort studies in Bangladesh conferring promising cure rates among patients with multidrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. Participants with rifampin-resistant tuberculosis that was susceptible to fluoroquinolones and aminoglycosides were included in this phase 3 noninferiority trial. In these patients, the short regimen was non-inferior with respect to the primary efficacy and had similar safety when compared to a long regimen.

Methods

  • Participants were randomized in a 2:1 ratio to receive either a short regimen (9-11 months) that included high-dose moxifloxacin or a long regimen (20 months) that followed the 2011 WHO guidelines.
  • The main efficacy outcome was favorable status at 132, based on Mycobacterium tuberculosis-negative cultures at 132 weeks and at a previous occasion, with no intervening positive culture or previous unfavorable outcome.
  • They determined noninferiority using an upper 95% confidence limit for the between-group difference in favorable status that was ≤ 10 percentage points.

Results

  • Researchers randomized 424 participants; approximately 90% comprised the modified intention-to-treat population.
  • In the long-regimen group and the short-regimen group, 79.8% and 78.8% of the participants, respectively, reported attainment of favorable status—a difference, with adjustment for human immunodeficiency virus status, of 1.0 percentage point (95% CI: −7.5 to 9.5; P=0.02 for noninferiority).
  • They attained consistent results with respect to noninferiority among the 321 participants in the per-protocol population (adjusted difference, –0.7 percentage points; 95% CI, −10.5 to 9.1).
  • Grade 3 or higher adverse events were reported in 45.4% and 48.2% of the participants in the long-regimen group and the short-regimen group, respectively.
  • Prolongation of either the QT interval or the corrected QT interval (calculated with Fridericia’s formula) to 500 msec occurred in 11.0% of participants and 6.4% of the participants in the short-regimen group and the long-regimen group, respectively (P=0.14); because of the greater incidence, participants in the short-regimen group were closely monitored and some received medication adjustments.
  • Death was reported for 8.5% of participants in the short-regimen group and 6.4% in the long-regimen group; acquired resistance to fluoroquinolones or aminoglycosides was reported in 3.3% and 2.3%, respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay